Abstract
The cell-cycle inhibitor p27 is a potential tumor suppressor, but its gene has never been found inactivated in human tumors1–4. Because cell-cycle regulation of p27 cellular abundance occurs at the post-transcriptional level5–7, we analyzed p27 protein expression and degradation in human colorectal carcinomas. Proteasome-mediated degradation activity of p27 was compared with its protein levels in a subset of tumor samples. We found that carcinomas with low or absent p27 protein displayed enhanced proteolytic activity specific for p27, suggesting that low p27 expression can result from increased proteasome-mediated degradation rather than altered gene expression. Patients whose tumors expressed p27 had a median survival of 151 months, whereas patients who lacked p27 (10%) had a median survival of 69 months. By multivariate analysis, p27 was found to be an independent prognostic marker. Lack of p27 was associated with poor prognosis (2.9 risk ratio for death; P = 0.003). The absence of p27 protein expression is thus a powerful negative prognostic marker in colorectal carcinomas, particularly in stage II tumors, and thereby may help in the selection of patients who will benefit from adjuvant therapy. These data suggest that aggressive tumors may result from the selection of a clone or clones that lack p27 due to increased proteasome-mediated degradation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kawamat, A.N. et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res. 55, 2266–2269 (1995).
Ponce-Castañeda, V. et al. p27Kip1: Chromosomal mapping to 12p12–12p13.1 and absence of mutations in human tumors. Cancer Res. 55, 1211–1214 (1995).
Pietenpol, J. et al. Assignment of the human p27Kip1 gene to 12pl 3 and its analysis in leukemias. Cancer Res. 55, 1206–1210 (1995).
Stegmaier, K. et al. Mutational analysis of the candidate tumor suppressor genes Tel and Kip1 in childhood acute lymphoblastic leukemia. Cancer Res. 56, 1413–1417 (1996).
Pagano, M. et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269, 682–685 (1995).
Hengst, L. & Reed, S. Translation control of p27Kip1 accumulation during the Cell cycle. Science 271, 1861–1864 (1996).
Yan, J. et al. Association of p27 mRNA with ribosomes regulates abundance of the cyclin-dependent inhibitor p27Kip1 as Cells withdraw from the Cell cycle. J. Biol. Chem. (in the press).
Maki, C., Hulbregtse, J. & Howley, P. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56, 2649–2654 (1996).
Committee on Cancer. Manual for Staging of Cancer, 4th edn. (eds. Beahrs, O.H., Henson, D.E., Mutter, R.V.P. & Kennedy, B.J., (Lippincott, New York, 1992).
Sahin, A. et al. Assessment of Ki-67-derived tumor proliferative activity in colorectal adenocarcinomas. Mod. Pathol. 7, 17–22 (1994).
Risio, M., Coverlizza, S., Ferrari, A., Candelaresi, G. & Rossini, S. Immunohistochemical study of epithelial Cell proliferation in hyperplastic polyps, adenomas, and adenocarcinomas of the large bowel. Gastroenterology 94, 899–906 (1988).
Brown, J.P. & Pagano, M. The mechanism of p53 degradation. Biochim. Biophys. Acta (in the press).
Loda, M. et al. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am. J. Pathol. 149, 1553–1564 (1996).
Kaplan, E.L. & Meier, P. Nonparametric estimation from incomplete observations. J. Am. Statist. Assoc. 53, 457–481 (1958).
Gehan, E.A. A generalized Wilcoxon test for comparing arbitrarily singly-censored data. Biometrika 52, 203–223 (1965).
Mantel, N. & Haenszel, W. Statistical aspect of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22, 719–749 (1959).
Cox, D. Regression models and life tables (with discussion). J. R. Statist. Soc. B. 34, 187–220 (1972).
Jonckheere, A.R. A distribution-free K-sample test against ordered alternatives. Biometrika 41, 133–145 (1954).
Kruskal, W.H. & Wallis, W.A. Use of ranks in one-criterion variance analysis. J. Am. Statist. Assoc. 47, 583–621 (1952).
Pagano, M., Pepperkok, R., Verde, F., Ansorge, W. & Draetta, G. Cyclin A is required at two points in the human Cell cycle. EMBO J. 11, 761–771 (1992).
Palombella, V., Rando, O., Goldberg, A. & Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78, 773–785 (1994).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Loda, M., Cukor, B., Tam, S. et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3, 231–234 (1997). https://doi.org/10.1038/nm0297-231
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0297-231
This article is cited by
-
Bacterial protein MakA causes suppression of tumour cell proliferation via inhibition of PIP5K1α/Akt signalling
Cell Death & Disease (2022)
-
Apigenin inhibits growth of melanoma by suppressing miR-512-3p and promoting the G1 phase of cell cycle involving the p27 Kip1 protein
Molecular and Cellular Biochemistry (2022)
-
Expression of p27 and p16 and their clinical significance in gastric cancer
Clinical and Translational Oncology (2021)
-
Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors
Oncogene (2020)
-
Targeting poor proteasomal function with radioiodine eliminates CT26 colon cancer stem cells resistant to bortezomib therapy
Scientific Reports (2020)